JQ1 was highly effective against preclinical models of several types of cancers with recurrent MYC amplifications, including acute myeloid leukemia, Burkitt's lymphoma and multiple myeloma, and efficacy was directly related to the extent of MYC suppression by treatment [20, 21]. The gene discussed is MYC; the disease is plasma cell myeloma.